Author

Magalie Boucher

Massachusetts Institute of TechnologyORCID 0009-0008-6293-6775Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Magalie Boucher1 paper · Institut universitaire de cardiologie et de pneumologie de Québec

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:CRISPR screen· 1 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1 Research Focus:protein design· 1

Frequent Co-Authors

Aidan KindoppiD· 1 shared Alexander D. StonemaniD· 1 shared Alexander SvanbergssoniD· 1 shared Andrea Li· 1 shared Apoorv ShankeriD· 1 shared Benjamin E. DevermaniD· 1 shared Cassandra Parada· 1 shared Chin-Yen Lin· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Aidan KindoppORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

NeurosciencebioRxivPreprintSep 29, 2026

BI-TfR1 CapX rapidly transits the blood-brain barrier for efficient, low-dose gene delivery throughout the CNS

Ken Y. Chan, Chin-Yen Lin, Qin Huang…·Benjamin E. Deverman

The paper describes BI-TfR1 CapX, a gene delivery vector that efficiently crosses the blood-brain barrier, transduces CNS neurons and astrocytes, and reduces Prnp mRNA with low doses.

DOI 10.64898/2026.09.23.753669

mouseDNA methylation

𝕏 PostBluesky

BioengineeringbioRxivPreprintJun 25, 2026

Engineering nanoparticle surface chemistry for antigen-presenting cell targeting improves specificity and safety of TLR3 agonist cancer immunotherapy

Victoria F. Gomerdinger, Cassandra Parada, Andrea Li…·Paula Therese Hammond

This paper develops a nanoparticle platform to target TLR3 agonist to antigen-presenting cells, improving cancer immunotherapy safety and efficacy by reducing systemic toxicity and enhancing tumor targeting.

1 citation

mouseexperimental assay

𝕏 PostBluesky